Clovis Oncology (CLVS) Market Value Declined While Cam Group Holding A Has Trimmed Position by $2.78 Million; Longfellow Investment Management Company Has Increased Its Sparton (SPA) Stake by $1.74 Million; Stock Price Declined

April 17, 2018 - By Ellis Scott

Sparton Corporation (NYSE:SPA) Logo

Cam Group Holding A decreased its stake in Clovis Oncology Inc (CLVS) by 19.43% based on its latest 2017Q4 regulatory filing with the SEC. Cam Group Holding A sold 40,927 shares as the company’s stock declined 18.56% with the market. The institutional investor held 169,700 shares of the health care company at the end of 2017Q4, valued at $11.54 million, down from 210,627 at the end of the previous reported quarter. Cam Group Holding A who had been investing in Clovis Oncology Inc for a number of months, seems to be less bullish one the $2.71 billion market cap company. The stock decreased 1.47% or $0.8 during the last trading session, reaching $53.61. About 4.13 million shares traded or 218.88% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 17, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Longfellow Investment Management Company Llc increased its stake in Sparton Corp (SPA) by 163.81% based on its latest 2017Q4 regulatory filing with the SEC. Longfellow Investment Management Company Llc bought 75,531 shares as the company’s stock declined 24.54% with the market. The institutional investor held 121,640 shares of the electrical products company at the end of 2017Q4, valued at $2.81 million, up from 46,109 at the end of the previous reported quarter. Longfellow Investment Management Company Llc who had been investing in Sparton Corp for a number of months, seems to be bullish on the $186.57 million market cap company. The stock decreased 0.16% or $0.03 during the last trading session, reaching $18.97. About 60,677 shares traded. Sparton Corporation (NYSE:SPA) has declined 15.82% since April 17, 2017 and is downtrending. It has underperformed by 27.37% the S&P500.

Investors sentiment increased to 1.5 in 2017 Q4. Its up 0.18, from 1.32 in 2017Q3. It is positive, as 11 investors sold SPA shares while 15 reduced holdings. 13 funds opened positions while 26 raised stakes. 6.01 million shares or 5.69% less from 6.38 million shares in 2017Q3 were reported. Royal Bank & Trust Of Canada stated it has 0% of its portfolio in Sparton Corporation (NYSE:SPA). Moreover, California Employees Retirement System has 0% invested in Sparton Corporation (NYSE:SPA). North Star Mngmt holds 1,146 shares or 0% of its portfolio. Aqr Cap Mgmt Ltd Liability has invested 0% in Sparton Corporation (NYSE:SPA). Franklin Res Incorporated reported 132,617 shares. Geode Cap Management Ltd Liability Corp invested in 0% or 74,289 shares. Moreover, Perritt Capital has 0.08% invested in Sparton Corporation (NYSE:SPA). 17,214 were reported by Ancora Advsrs Lc. Prelude Mngmt Ltd reported 52,732 shares. Bessemer Grp Inc Incorporated stated it has 7,609 shares or 0% of all its holdings. Cubist Systematic Strategies Limited Liability Co has 0.03% invested in Sparton Corporation (NYSE:SPA). Pub Employees Retirement Sys Of Ohio owns 114,000 shares. Css Lc Il reported 0.04% of its portfolio in Sparton Corporation (NYSE:SPA). State Board Of Administration Of Florida Retirement reported 0% of its portfolio in Sparton Corporation (NYSE:SPA). Point72 Asia (Hong Kong) Limited holds 0% or 163 shares.

Among 3 analysts covering Sparton Corp (NYSE:SPA), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Sparton Corp had 4 analyst reports since October 5, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by CJS Securities given on Tuesday, September 20. Sidoti initiated Sparton Corporation (NYSE:SPA) on Monday, October 5 with “Buy” rating. The stock has “Neutral” rating by Sidoti on Wednesday, May 4. As per Thursday, February 4, the company rating was upgraded by B. Riley & Co.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It dived, as 35 investors sold CLVS shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. Moreover, Fmr Ltd has 0.02% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Moore Cap Ltd Partnership accumulated 25,000 shares. Legal & General Group Public Limited invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Jefferies Group Ltd Liability holds 2,937 shares. Savings Bank Of Montreal Can holds 5,083 shares. New Jersey-based Lord Abbett Ltd Com has invested 0.04% in Clovis Oncology, Inc. (NASDAQ:CLVS). Legacy Private Trust reported 0.03% stake. Rice Hall James Limited Liability Company reported 0.39% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). 34,250 are owned by Proshare Advsr Ltd. The Tennessee-based First Mercantile Trust has invested 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS). Great West Life Assurance Can has 6,404 shares for 0% of their portfolio. California State Teachers Retirement Systems owns 69,270 shares. Emerald Advisers Inc Pa invested in 260,069 shares. Healthcor Mngmt Ltd Partnership has 2.16% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 973,840 shares. Sei Investments holds 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 10,379 shares.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 64 analyst reports since September 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, June 20 by Janney Capital. The rating was maintained by Credit Suisse with “Buy” on Tuesday, July 18. The firm earned “Buy” rating on Monday, September 18 by Leerink Swann. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Friday, January 27 by Bank of America. The company was reinitiated on Monday, April 4 by Piper Jaffray. Morgan Stanley initiated Clovis Oncology, Inc. (NASDAQ:CLVS) on Friday, January 13 with “Overweight” rating. The firm has “Buy” rating given on Wednesday, September 6 by J.P. Morgan. The firm earned “Buy” rating on Monday, July 31 by Leerink Swann. Suntrust Robinson maintained the shares of CLVS in report on Wednesday, August 24 with “Buy” rating. Chardan Capital Markets upgraded the stock to “Neutral” rating in Monday, June 19 report.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on May, 2. They expect $-1.34 earnings per share, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.27 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 5.51% negative EPS growth.

Cam Group Holding A, which manages about $6.92B US Long portfolio, upped its stake in Priceline Grp Inc (NASDAQ:PCLN) by 1,934 shares to 109,342 shares, valued at $190.01 million in 2017Q4, according to the filing. It also increased its holding in Stemline Therapeutics Inc (NASDAQ:STML) by 35,437 shares in the quarter, for a total of 195,437 shares, and has risen its stake in Home Depot Inc (NYSE:HD).

Sparton Corporation (NYSE:SPA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: